Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.rlu.0000249545.85131.5f | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alkaptonuria: a rare disease with multiorgan manifestation and a long-awaited diagnosis.
BMJ Case Rep
December 2024
Lungemedicinsk, Vejle Sygehus, Vejle, Denmark.
Alkaptonuria is a rare inherited disease resulting from a genetic variant leading to homogentisic acid accumulation in body tissues, causing a broad spectrum of symptoms. Our case involves a Caucasian male diagnosed in his 70s, who shares a constellation of symptoms and the diagnosis with his monozygotic twin brother. The symptoms include early-onset arthropathy, tendinopathy, osteopenia, discolouration of the auricular regions and fingers, scleral discolouration, secondary glaucoma, proteinuria, calcification of the mitral valve and black urethral and prostate stones.
View Article and Find Full Text PDFLeptin levels are associated with coronary artery calcification in patients with advanced prostate cancer.
Oncologist
November 2024
Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Background: Convergent data suggest that advanced prostate cancer and coronary heart disease (CHD) share biological vulnerabilities that may be linked to adiposity. Here we explore whether leptin, as a marker and mediator of adiposity, could link prostate cancer to CHD.
Methods: Patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a phase II trial (NCT02703623) studying androgen deprivation therapy, abiraterone, prednisone, and apalutamide were eligible if they had plasma and a chest CT scan available.
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy.
Brachytherapy
November 2024
Carleton Laboratory for Radiotherapy Physics, Physics Department, Carleton University, Ottawa, Ontario, Canada. Electronic address:
Purpose: Demonstrate quantitative characterization of 3D patient-specific absorbed dose distributions using Haralick texture analysis, and interpret measures in terms of underlying physics and radiation dosimetry.
Methods: Retrospective analysis is performed for 137 patients who underwent permanent implant prostate brachytherapy using two simulation conditions: "TG186" (realistic tissues including 0-3.8% intraprostatic calcifications; interseed attenuation) and "TG43" (water-model; no interseed attenuation).
Prostatic stents: a systematic review and analysis of functional outcomes and complication rate.
Prostate Cancer Prostatic Dis
November 2024
University Hospital Southampton NHS Trust, Southampton, UK.
Background: This review aims to identify and summarize the current literature on the use of prostatic stents or nitinol devices as minimally invasive techniques for the management of lower urinary tract symptoms (LUTS) resulting from benign prostatic hyperplasia (BPH).
Methods: A comprehensive search of the literature was conducted until October 2023. Only original articles written in English were considered for inclusion.
Extra-Skeletal Osteosarcoma of the Prostate After Treated Prostatic Acinar Adenocarcinoma: A Case Report and Review of the Literature.
Int J Surg Pathol
October 2024
Pathology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Article Synopsis
- Extra-skeletal osteosarcoma is an uncommon and aggressive type of soft tissue cancer, and this case highlights its rare occurrence in the prostate.
- A 58-year-old man initially diagnosed with prostate adenocarcinoma experienced treatment but had a recurrence of a more aggressive tumor, resulting in additional complications.
- Despite aggressive treatment, including chemotherapy, the disease progressed to metastasize to the lungs and liver, ultimately leading to the patient's death.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!